IPCA LABORATORIES LTD.

Ipca Laboratories Ltd. announced its Board of Directors has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger is subject to regulatory approvals. The Appointed Date for the scheme is April 1, 2026. Ipca Laboratories had a total income of ₹7431 Crores for FY26, while Krebs Biochemicals had ₹26 Crores. The transaction is considered a related party transaction but will be conducted on an arm's length basis. Both companies operate in pharmaceutical manufacturing and marketing. The rationale includes operational synergies, cost optimization, business consolidation, and securing supply chains for key APIs and intermediates. Krebs Biochemicals possesses manufacturing capabilities for fermentation-based APIs that Ipca lacks. No cash consideration will be paid; instead, Ipca will issue 7 equity shares for every 200 shares of Krebs.

Ipca Laboratories Ltd. announced its Board of Directors has approved the Scheme of Amalgamation of Krebs Biochemicals & Industries Ltd. with Ipca Laboratories Ltd. The merger is subject to regulatory approvals. The Appointed Date for the scheme is April 1, 2026. Ipca Laboratories had a total income of ₹7431 Crores for FY26, while Krebs Biochemicals had ₹26 Crores. The transaction is considered a related party transaction but will be conducted at arm's length. Both companies operate in pharmaceutical manufacturing and marketing. The rationale includes operational synergies, cost optimization, business consolidation, and securing supply of key APIs and intermediates. No cash consideration will be paid; instead, an equity share exchange ratio of 7 shares of Ipca for every 200 shares of Krebs will be implemented.

Ipca Laboratories Ltd has announced the closure of its trading window for dealing in the company's securities by insiders. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from July 1, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the first quarter ended June 30, 2026. The exact date of the board meeting to consider these results will be communicated separately.

Ipca Laboratories and Bhami’s Research Laboratory (BRL) have entered into a global licensing agreement. This collaboration grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform. The agreement focuses on the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. Ipca will handle further research, clinical trials, manufacturing, and launch, while BRL will manage proof-of-concept and formulation development. BRL will receive milestone fees and royalties on net sales upon commercialization. This partnership aims to accelerate the development of affordable biologics for cancer and autoimmune diseases, enhancing patient convenience and safety.

Ipca Laboratories Ltd has announced a revised passcode link for the conference call to discuss the company's Q4FY26 earnings and business update. The conference call is scheduled for today, Monday, 18th June 2026, at 15:30 hrs IST. The revised Diamond Passcode link is provided in the announcement.

Ipca Laboratories Ltd's board has recommended a dividend of ₹6 per share (600%) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The record date for dividend entitlement is fixed as August 7, 2026. Additionally, the board approved the re-appointment of Mr. Prashant Godha as Executive Director for another 5 years, effective August 16, 2026, also subject to shareholder approval. The Board Meeting started at 11.30 a.m. and concluded at 1.45 p.m.

Ipca Laboratories Ltd's Board of Directors has approved the re-appointment of Mr. Prashant Godha as Executive Director for a further period of 5 years, effective from August 16, 2026. This re-appointment is subject to shareholder approval at the upcoming Annual General Meeting. The board also approved the audited financial results for the year ended March 31, 2026, and recommended a dividend of ₹6 per share.

Ipca Laboratories Ltd has announced its Standalone and Consolidated Results for Q4FY26. The Board of Directors has recommended a dividend of ₹6 per share (600%) subject to shareholder approval, with a record date fixed as August 7, 2026. Additionally, the board approved the re-appointment of Mr. Prashant Godha as Executive Director for another 5 years effective August 16, 2026, also subject to shareholder approval. Standalone revenue from operations for the year ended March 31, 2026, stood at ₹7,336.75 Cr.

Ipca Laboratories Ltd's Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹6 per share (600%) subject to shareholder approval. Mr. Prashant Godha's re-appointment as Executive Director for 5 years was also approved, effective August 16, 2026, subject to shareholder approval. The Board Meeting was held on May 15, 2024, from 11:30 a.m. to 1:45 p.m.

Ipca Laboratories Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the standalone and consolidated audited financial results for the fourth quarter and financial year ended March 31, 2026. The board will also consider the recommendation of a dividend for the financial year 2025-26. The trading window for insiders remains closed from April 1, 2026, until 48 hours after the declaration of the results, i.e., until May 31, 2026.